Healthy Volunteers Clinical Trial
Official title:
Adverse Effects of RBC Transfusions: A Unifying Hypothesis
Transfusion of red blood cells is often used in critically ill patients with low red blood
cell counts to prevent disease progression and death. Recent studies suggest that the use of
"aged" versus "fresh" red blood cells are associated with worse clinical outcomes. There is
evidence that red blood cells work with the cells lining our blood vessels to produce a
variety of substances that normally cause arteries to relax and increase blood supply. Two
of these substances are called nitric oxide (NO) and endothelium-derived hyperpolarizing
factor (EDHF). The investigators are trying to determine the nature of these substances in
human beings when they are transfused "aged" versus "fresh" red blood cells. It is their
thought that "aged" red blood cells have less of the substances (NO and EDHF) that naturally
relax our arteries and further changes the blood supply. One way to determine this is to
transfuse a subject's own "aged" and "fresh" red blood cells and inject substances such as
L-NMMA (L-NG monomethyl arginine) and TEA (tetraethylammonium chloride), which block the
production of NO and EDHF respectively, and then, study what happens to the blood flow.
There is evidence that red blood cells produce NO, which normally causes arteries to relax
and increase blood supply. The investigators will try to determine the nature of NO in red
blood cells and whether the amount of this substance is altered because of different blood
processing and storage techniques. It is their thought that "aged" red blood cells have less
NO that naturally relaxes our arteries and further changes the blood supply. This study is
designed to determine the most ideal way of storing and processing blood.
Transfusion of red blood cells (RBCs) is often effective at preventing morbidity and
mortality in anemic patients. In contrast, recent studies indicate that some RBC components
may have functional defects ("RBC storage lesions") that actually cause morbidity and
mortality when transfused. For example, patients transfused with RBCs stored >14 days have
statistically worse outcomes than those receiving "fresher" RBC units. In addition to the
age of stored RBCs, the volume transfused may be important. The TRICC study showed that
specific patients whose transfusions were limited by a restrictive trigger (RBCs
transfusions only when hemoglobin [Hb] < 7 g/dL) had significantly better outcomes than
those transfused with a more liberal trigger ([Hb] < 10 g/dL Hb). This finding has been
particularly difficult to understand since conventional wisdom suggests that an elevated
[Hb] should be beneficial because it supports increased O2 delivery. Recipient-specific
factors may also contribute to the occurrence of these adverse events. Unfortunately, these
events have been difficult to investigate because up to now they have existed only as
"statistical occurrences" of increased morbidity and mortality in large data sets. There are
currently no clinical or laboratory methods to detect or study them in individual patients.
The microcirculation is composed of a continuum of small vessels including small arterioles,
capillaries, and post-capillary venules. The microcirculation represents an
actively-adjusting vascular circuit that matches blood flow (and O2 delivery) to local
tissue oxygen demands. While the physiologic mechanisms that match O2 delivery to local
requirements are incompletely understood, endothelium-derived nitric oxide (NO) clearly
plays an important role. Interestingly, recent work has revealed that in addition to
transporting O2 and CO2, the RBC also controls local NO concentrations and thus may also
play a surprisingly important role in regulating blood flow in the microcirculation.
Herein, the investigators bring together previously unconnected data to propose a unifying
hypothesis, centered on insufficient NO bioavailability (INOBA), to explain the increased
morbidity and mortality observed in some patients following RBC transfusion. In this model,
variables associated with RBC units (storage time; 2,3-DPG concentration) and transfusion
recipients (endothelial dysfunction; hematocrit [Hct]) collectively lead to changes in NO
levels in vascular beds. Under certain circumstances, these variables are "aligned" such
that NO concentrations are markedly reduced, leading to vasoconstriction, decreased local
blood flow and insufficient O2 delivery to end organs. Under these circumstances, the
likelihood of morbidity and mortality escalates. The INOBA hypothesis is attractive because
of its explanatory power and because it leads to a number of readily testable predictions,
which will be investigated in the following aims:
Aim 1: To investigate the effects of blood processing and storage (using standard
FDA-approved conditions) on NO production and scavenging by human RBCs/Hb in vitro. Using
sensitive biochemical assays (electron spin resonance [ESR]) and a rat aortic ring in vitro
bioassay, the investigators will test the effects of RBC storage time, leukoreduction, and
irradiation on NO synthesis and/or scavenging by intact RBCs and free Hb. Modifications such
as washing and rejuvenation will be investigated as possible approaches to correct
abnormalities in NO bioavailability.
Aim 2: To transfuse healthy volunteers and investigate the effects of storage-related RBC
changes on blood flow, tissue oxygenation, and biomarkers of cardiovascular function. The
investigators will determine whether RBCs prepared and stored under conditions that alter NO
bioavailability in vitro (Aim 1) inhibit NO-mediated vasodilation, reduce tissue perfusion,
and decrease tissue O2 delivery in healthy transfusion recipients in vivo. The role of
2,3-DPG depletion as well as exercise-induced O2 demand will also be investigated with these
specialized experimental systems.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05029518 -
3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability
|
Phase 1 | |
| Completed |
NCT05001152 -
Taste Assessment of Ozanimod
|
Phase 1 | |
| Completed |
NCT04493255 -
A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants
|
Phase 1 | |
| Completed |
NCT03457649 -
IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT00995891 -
Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
|
||
| Completed |
NCT05050318 -
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
|
Phase 4 | |
| Completed |
NCT05043766 -
Evaluation of Oral PF614 Relative to OxyContin
|
Phase 1 | |
| Completed |
NCT04466748 -
A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects
|
Phase 1 | |
| Completed |
NCT00746733 -
Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
|
Phase 1 | |
| Recruiting |
NCT05929651 -
Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy
|
Phase 4 | |
| Completed |
NCT05954039 -
Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect
|
N/A | |
| Completed |
NCT05045716 -
A Study of Subcutaneous Lecanemab in Healthy Participants
|
Phase 1 | |
| Active, not recruiting |
NCT02747927 -
Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
|
Phase 3 | |
| Completed |
NCT05533801 -
A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants
|
Phase 1 | |
| Not yet recruiting |
NCT03931369 -
Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)
|
Phase 2 | |
| Completed |
NCT03279146 -
A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT06027437 -
A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
|
Phase 1 | |
| Recruiting |
NCT05619874 -
Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity
|
N/A | |
| Completed |
NCT05553418 -
Investigational On-body Injector Clinical Study
|
N/A | |
| Completed |
NCT04092712 -
Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers
|
Phase 1 |